About Us

Advancing Non-Invasive Healthcare

In 2015 Nonacus was founded with a singular purpose: to offer high quality, non-invasive, genetic testing with the end-user at the forefront. Formed by a dedicated group of biotechnology professionals with over 35 years of experience within the sector, Nonacus understands the need for laboratories to continually deliver progress. This understanding forms the basis of all our products and drives our innovation.

Scientist working in a lab

Our Mission and Purpose

Nonacus staff stood together in Nonacus lab coats

Our Mission

Our goal is to democratize non-invasive genetic testing globally with a focus on oncology so that we can enable decentralized, cost-effective and cutting-edge cancer detection and longitudinal patient monitoring.

Our Purpose

Detecting cancer earlier and informing patient outcomes through the deployment of a truly innovative liquid biopsy testing platform.

The Nonacus Name

When Chris and Lee founded Nonacus in 2015 they had a singular purpose - to develop non-invasive DNA tests that would change the way genomic diagnostics was done.

Choosing a name that would reflect this mission wasn't easy.

Based off the Latin term ‘non acus’ meaning ‘no needle’, Nonacus accurately symbolises the company’s mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing. To read more about the story behind the name click here.

Nonacus Testing kit

ISO 13485:2016 Certification

At Nonacus, we are deeply committed to delivering unparalleled quality and precision in biotechnology.

Our dedication to excellence is underscored by our ISO 13485:2016 BSI certificate, an internationally recognized standard for medical device quality management.

Read Our Latest Insights

GALEAS Hereditary Plus

New genetic test to speed up and streamline diagnosis of inherited cancers

January 24, 2024

Genetic testing company, Nonacus, has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS Hereditary Plus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations.

Read More

Genetic testing for hereditary cancers: challenges and opportunities for genomic centres

December 20, 2023

Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.

Read More

4 key factors influencing NGS custom panel design

December 8, 2023

Effective probe-set design ensures comprehensive target coverage and heightened sensitivity. A poor design can lead to missed opportunities in detecting critical genetic variants.

Read More